Skip to main content
Erschienen in: Tumor Biology 12/2015

01.12.2015 | Research Article

Identification of RAB2A and PRDX1 as the potential biomarkers for oral squamous cell carcinoma using mass spectrometry-based comparative proteomic approach

verfasst von: Kaushik Kumar Dey, Ipsita Pal, Rashmi Bharti, Goutam Dey, B. N. Prashanth Kumar, Shashi Rajput, Aditya Parekh, Sheetal Parida, Priyanka Halder, Indranil Kulavi, Mahitosh Mandal

Erschienen in: Tumor Biology | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Abstract

Despite the recent advances in diagnostic and therapeutic strategies, oral squamous cell carcinoma (OSCC) remains a major health burden. Protein biomarker discovery for early detection will help to improve patient survival rate in OSCC. Mass spectrometry-based proteomics has emerged as an excellent approach for detection of protein biomarkers in various types of cancers. In the current study, we have used 4-Plex isobaric tags for relative and absolute quantitation (iTRAQ)-based shotgun quantitative proteomic approach to identify proteins that are differentially expressed in cancerous tissues compared to normal tissues. The high-resolution mass spectrometric analysis resulted in identifying 2,074 proteins, among which 288 proteins were differentially expressed. Further, it was noticed that 162 proteins were upregulated, while 125 proteins were downregulated in OSCC-derived cancer tissue samples as compared to the adjacent normal tissues. We identified some of the known molecules which were reported earlier in OSCC such as MMP-9 (8.4-fold), ZNF142 (5.6-fold), and S100A7 (3.5-fold). Apart from this, we have also identified some novel signature proteins which have not been reported earlier in OSCC including ras-related protein Rab-2A isoform, RAB2A (4.6-fold), and peroxiredoxin-1, PRDX1 (2.2-fold). The immunohistochemistry-based validation using tissue microarray slides in OSCC revealed overexpression of the RAB2A and PRDX1 gene in 80 and 68 % of the tested clinical cases, respectively. This study will not only serve as a resource of candidate biomarkers but will contribute towards the existing knowledge on the role of the candidate molecules towards disease progression and therapeutic potential.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Ni YH, Ding L, Hu QG, Hua ZC. Potential biomarkers for oral squamous cell carcinoma: proteomics discovery and clinical validation. Proteomics: Clin Appl. 2015;9(1-2):86–97. doi:10.1002/prca.201400091. Ni YH, Ding L, Hu QG, Hua ZC. Potential biomarkers for oral squamous cell carcinoma: proteomics discovery and clinical validation. Proteomics: Clin Appl. 2015;9(1-2):86–97. doi:10.​1002/​prca.​201400091.
4.
Zurück zum Zitat Perez-Sayans M, Somoza-Martin JM, Barros-Angueira F, Reboiras-Lopez MD, Gandara Rey JM, Garcia-Garcia A. Genetic and molecular alterations associated with oral squamous cell cancer (review). Oncol Rep. 2009;22(6):1277–82.CrossRefPubMed Perez-Sayans M, Somoza-Martin JM, Barros-Angueira F, Reboiras-Lopez MD, Gandara Rey JM, Garcia-Garcia A. Genetic and molecular alterations associated with oral squamous cell cancer (review). Oncol Rep. 2009;22(6):1277–82.CrossRefPubMed
7.
Zurück zum Zitat Turhani D, Krapfenbauer K, Thurnher D, Langen H, Fountoulakis M. Identification of differentially expressed, tumor-associated proteins in oral squamous cell carcinoma by proteomic analysis. Electrophoresis. 2006;27(7):1417–23. doi:10.1002/elps.200500510.CrossRefPubMed Turhani D, Krapfenbauer K, Thurnher D, Langen H, Fountoulakis M. Identification of differentially expressed, tumor-associated proteins in oral squamous cell carcinoma by proteomic analysis. Electrophoresis. 2006;27(7):1417–23. doi:10.​1002/​elps.​200500510.CrossRefPubMed
8.
Zurück zum Zitat Marimuthu A, Chavan S, Sathe G, Sahasrabuddhe NA, Srikanth SM, Renuse S, et al. Identification of head and neck squamous cell carcinoma biomarker candidates through proteomic analysis of cancer cell secretome. Biochim Biophys Acta. 2013;1834(11):2308–16. doi:10.1016/j.bbapap.2013.04.029.CrossRefPubMed Marimuthu A, Chavan S, Sathe G, Sahasrabuddhe NA, Srikanth SM, Renuse S, et al. Identification of head and neck squamous cell carcinoma biomarker candidates through proteomic analysis of cancer cell secretome. Biochim Biophys Acta. 2013;1834(11):2308–16. doi:10.​1016/​j.​bbapap.​2013.​04.​029.CrossRefPubMed
10.
Zurück zum Zitat Syed N, Chavan S, Sahasrabuddhe NA, Renuse S, Sathe G, Nanjappa V, et al. Silencing of high-mobility group box 2 (HMGB2) modulates cisplatin and 5-fluorouracil sensitivity in head and neck squamous cell carcinoma. Proteomics. 2015;15(2-3):383–93. doi:10.1002/pmic.201400338.CrossRefPubMedPubMedCentral Syed N, Chavan S, Sahasrabuddhe NA, Renuse S, Sathe G, Nanjappa V, et al. Silencing of high-mobility group box 2 (HMGB2) modulates cisplatin and 5-fluorouracil sensitivity in head and neck squamous cell carcinoma. Proteomics. 2015;15(2-3):383–93. doi:10.​1002/​pmic.​201400338.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Franchi A, Santucci M, Masini E, Sardi I, Paglierani M, Gallo O. Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck. Cancer. 2002;95(9):1902–10. doi:10.1002/cncr.10916.CrossRefPubMed Franchi A, Santucci M, Masini E, Sardi I, Paglierani M, Gallo O. Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck. Cancer. 2002;95(9):1902–10. doi:10.​1002/​cncr.​10916.CrossRefPubMed
13.
Zurück zum Zitat Miyake N, Katoh O, Hirata S, Kimura S, Watanabe H, Yajin K. Expression of the Kruppel-type zinc finger gene, ZK7, in head and neck squamous cell carcinoma and normal mucosa. Cancer Lett. 2002;185(1):111–8.CrossRefPubMed Miyake N, Katoh O, Hirata S, Kimura S, Watanabe H, Yajin K. Expression of the Kruppel-type zinc finger gene, ZK7, in head and neck squamous cell carcinoma and normal mucosa. Cancer Lett. 2002;185(1):111–8.CrossRefPubMed
15.
Zurück zum Zitat Kaur J, Ralhan R. Differential expression of 70-kDa heat shock-protein in human oral tumorigenesis. Int J Cancer. 1995;63(6):774–9.CrossRefPubMed Kaur J, Ralhan R. Differential expression of 70-kDa heat shock-protein in human oral tumorigenesis. Int J Cancer. 1995;63(6):774–9.CrossRefPubMed
17.
Zurück zum Zitat Feher LZ, Pocsay G, Krenacs L, Zvara A, Bagdi E, Pocsay R, et al. Amplification of thymosin beta 10 and AKAP13 genes in metastatic and aggressive papillary thyroid carcinomas. Pathol Oncol Res. 2012;18(2):449–58. doi:10.1007/s12253-011-9467-7.CrossRefPubMed Feher LZ, Pocsay G, Krenacs L, Zvara A, Bagdi E, Pocsay R, et al. Amplification of thymosin beta 10 and AKAP13 genes in metastatic and aggressive papillary thyroid carcinomas. Pathol Oncol Res. 2012;18(2):449–58. doi:10.​1007/​s12253-011-9467-7.CrossRefPubMed
18.
Zurück zum Zitat Herold-Mende C, Andl T, Laemmler F, Reisser C, Eichhorn S. Expression and localization profile of tenascin in squamous cell carcinomas of the head and neck. HNO. 1999;47(8):723–9.CrossRefPubMed Herold-Mende C, Andl T, Laemmler F, Reisser C, Eichhorn S. Expression and localization profile of tenascin in squamous cell carcinomas of the head and neck. HNO. 1999;47(8):723–9.CrossRefPubMed
20.
23.
Zurück zum Zitat Barbaud A, Simon M, Parache RM, Serre G. Immunohistochemical characterization of the differentiation state of basal cell carcinomas with special interest for infiltrating relapsing tumors. Eur J Dermatol. 1998;8(5):320–4.PubMed Barbaud A, Simon M, Parache RM, Serre G. Immunohistochemical characterization of the differentiation state of basal cell carcinomas with special interest for infiltrating relapsing tumors. Eur J Dermatol. 1998;8(5):320–4.PubMed
28.
Zurück zum Zitat Leygue E, Snell L, Dotzlaw H, Hole K, Hiller-Hitchcock T, Roughley PJ, et al. Expression of lumican in human breast carcinoma. Cancer Res. 1998;58(7):1348–52.PubMed Leygue E, Snell L, Dotzlaw H, Hole K, Hiller-Hitchcock T, Roughley PJ, et al. Expression of lumican in human breast carcinoma. Cancer Res. 1998;58(7):1348–52.PubMed
29.
Zurück zum Zitat Naito Z, Ishiwata T, Kurban G, Teduka K, Kawamoto Y, Kawahara K, et al. Expression and accumulation of lumican protein in uterine cervical cancer cells at the periphery of cancer nests. Int J Oncol. 2002;20(5):943–8.PubMed Naito Z, Ishiwata T, Kurban G, Teduka K, Kawamoto Y, Kawahara K, et al. Expression and accumulation of lumican protein in uterine cervical cancer cells at the periphery of cancer nests. Int J Oncol. 2002;20(5):943–8.PubMed
30.
Zurück zum Zitat Sun J, Feng X, Gao S, Xiao Z. microRNA-338-3p functions as a tumor suppressor in human non-small-cell lung carcinoma and targets Ras-related protein 14. Mol Med Rep. 2015;11(2):1400–6. doi:10.3892/mmr.2014.2880.PubMed Sun J, Feng X, Gao S, Xiao Z. microRNA-338-3p functions as a tumor suppressor in human non-small-cell lung carcinoma and targets Ras-related protein 14. Mol Med Rep. 2015;11(2):1400–6. doi:10.​3892/​mmr.​2014.​2880.PubMed
31.
Zurück zum Zitat Yoshida H, Miyachi M, Ouchi K, Kuwahara Y, Tsuchiya K, Iehara T, et al. Identification of COL3A1 and RAB2A as novel translocation partner genes of PLAG1 in lipoblastoma. Genes, Chromosomes Cancer. 2014;53(7):606–11. doi:10.1002/gcc.22170.CrossRefPubMed Yoshida H, Miyachi M, Ouchi K, Kuwahara Y, Tsuchiya K, Iehara T, et al. Identification of COL3A1 and RAB2A as novel translocation partner genes of PLAG1 in lipoblastoma. Genes, Chromosomes Cancer. 2014;53(7):606–11. doi:10.​1002/​gcc.​22170.CrossRefPubMed
32.
33.
Zurück zum Zitat Wood ZA, Schroder E, Robin Harris J, Poole LB. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci. 2003;28(1):32–40.CrossRefPubMed Wood ZA, Schroder E, Robin Harris J, Poole LB. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci. 2003;28(1):32–40.CrossRefPubMed
34.
35.
Zurück zum Zitat Yanagawa T, Ishikawa T, Ishii T, Tabuchi K, Iwasa S, Bannai S, et al. Peroxiredoxin I expression in human thyroid tumors. Cancer Lett. 1999;145(1-2):127–32.CrossRefPubMed Yanagawa T, Ishikawa T, Ishii T, Tabuchi K, Iwasa S, Bannai S, et al. Peroxiredoxin I expression in human thyroid tumors. Cancer Lett. 1999;145(1-2):127–32.CrossRefPubMed
36.
Zurück zum Zitat Kim JH, Bogner PN, Ramnath N, Park Y, Yu J, Park YM. Elevated peroxiredoxin 1, but not NF-E2-related factor 2, is an independent prognostic factor for disease recurrence and reduced survival in stage I non-small cell lung cancer. Clin Cancer Res. 2007;13(13):3875–82. doi:10.1158/1078-0432.CCR-06-2893.CrossRefPubMed Kim JH, Bogner PN, Ramnath N, Park Y, Yu J, Park YM. Elevated peroxiredoxin 1, but not NF-E2-related factor 2, is an independent prognostic factor for disease recurrence and reduced survival in stage I non-small cell lung cancer. Clin Cancer Res. 2007;13(13):3875–82. doi:10.​1158/​1078-0432.​CCR-06-2893.CrossRefPubMed
37.
Zurück zum Zitat Neumann CA, Krause DS, Carman CV, Das S, Dubey DP, Abraham JL, et al. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature. 2003;424(6948):561–5. doi:10.1038/nature01819.CrossRefPubMed Neumann CA, Krause DS, Carman CV, Das S, Dubey DP, Abraham JL, et al. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature. 2003;424(6948):561–5. doi:10.​1038/​nature01819.CrossRefPubMed
38.
Zurück zum Zitat Kim YJ, Lee WS, Ip C, Chae HZ, Park EM, Park YM. Prx1 suppresses radiation-induced c-Jun NH2-terminal kinase signaling in lung cancer cells through interaction with the glutathione S-transferase Pi/c-Jun NH2-terminal kinase complex. Cancer Res. 2006;66(14):7136–42. doi:10.1158/0008-5472.CAN-05-4446.CrossRefPubMed Kim YJ, Lee WS, Ip C, Chae HZ, Park EM, Park YM. Prx1 suppresses radiation-induced c-Jun NH2-terminal kinase signaling in lung cancer cells through interaction with the glutathione S-transferase Pi/c-Jun NH2-terminal kinase complex. Cancer Res. 2006;66(14):7136–42. doi:10.​1158/​0008-5472.​CAN-05-4446.CrossRefPubMed
Metadaten
Titel
Identification of RAB2A and PRDX1 as the potential biomarkers for oral squamous cell carcinoma using mass spectrometry-based comparative proteomic approach
verfasst von
Kaushik Kumar Dey
Ipsita Pal
Rashmi Bharti
Goutam Dey
B. N. Prashanth Kumar
Shashi Rajput
Aditya Parekh
Sheetal Parida
Priyanka Halder
Indranil Kulavi
Mahitosh Mandal
Publikationsdatum
01.12.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 12/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3758-7

Weitere Artikel der Ausgabe 12/2015

Tumor Biology 12/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.